IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test

@inproceedings{Holst2015IDegLiraIB,
  title={IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test},
  author={Jens Juul Holst and John B Buse and Helena W Rodbard and Sultan Linjawi and Vincent Woo and Trine Well\ov Boesgaard and Kajsa Kvist and Stephen C. L. Gough},
  booktitle={Journal of diabetes science and technology},
  year={2015}
}
OBJECTIVE IDegLira is a novel, fixed-ratio combination of the long-acting basal insulin, insulin degludec, and the long-acting glucagon-like peptide-1 analog liraglutide. We studied the effect of IDegLira versus its components on postprandial glucose (PPG) in type 2 diabetes. METHODS In this substudy, 260 (15.6%) of the original 1663 patients with inadequate glycemic control participating in a 26-week, open-label trial (DUAL I) were randomized 2:1:1 to once-daily IDegLira, insulin degludec or… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 5 times. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 26 references

An overview of the pharmacokinetics, efficacy and safety of liraglutide.

Diabetes research and clinical practice • 2012
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…